The S&P 500 Index ($SPX) (SPY) today is up +0.08%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.26%, and the ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

The S&P 500 Index ($SPX) (SPY) today is up +0.29%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.18%. March E-mini S&P futures (ESH25) are ...

Medicaid MCR is forecasted at 89.9% for 2025, with most rate increases already known. Medicare is expected to see a slightly elevated MCR above target due to utilization pressure and suboptimal recent ...

HII's Q4 revenues total $3 billion, which miss the Zacks Consensus Estimate by 0.9%. The top line declines 5.4% year over ...

Reports Q4 revenue $829.4M, consensus $827.43M. CEO Ivo Jurek commented, “In 2024, we generated a 180 basis point increase in our gross margin ...

Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on ...

ConocoPhillips (NYSE: COP) reported Q4 results, with $14.74B revenue and $1.98 EPS, surpassing expectations. Company also announced dividends and production targets for 2025.

Adjusted EBITDA of $996 M for the fourth quarter, $3,684 Mfor the full year;R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x ;R&D Solutions contracted ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.